Company news

Jazz Pharmaceuticals plc news in 2024

Jazz Pharmaceuticals plc's news releases, calls and decks from 2024, newest first.

View company

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

Jazz Pharmaceuticals Announces CEO Succession Plan

December 15, 2024

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

December 5, 2024

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

December 4, 2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

December 3, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

December 2, 2024

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 19, 2024

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

November 18, 2024

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

November 5, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

October 30, 2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

October 22, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 14, 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

September 15, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

September 8, 2024

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

September 4, 2024

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

September 3, 2024

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

September 2, 2024

Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

August 21, 2024

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 20, 2024

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance

July 30, 2024

Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

July 24, 2024

Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026

July 21, 2024

Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024

July 16, 2024

Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

July 8, 2024

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

June 19, 2024

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

May 31, 2024

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

May 29, 2024

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

May 28, 2024

Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

May 21, 2024

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference

April 30, 2024

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance

April 30, 2024

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

April 23, 2024

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

April 16, 2024

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

April 9, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

April 1, 2024

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

March 11, 2024

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

February 27, 2024

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

February 26, 2024

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

February 20, 2024

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 19, 2024

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

February 13, 2024

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

February 6, 2024

Calls in 2024

Decks in 2024